VCAM1 and atherosclerosis: The authors suggested conjugating antibodies or binding peptides to target inflammatory markers, such as vascular cell adhesion molecule 1 (VCAM-1) for atherosclerosis and neutrophil cytosolic factor 1 for rheumatoid arthritis [159].